drugset / Trial / NCT07028268

A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors

NCT07028268

Phase 2 Recruiting 210 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the efficacy, and safety of SHR-2017 Injection in Patients with Bone Metastases from Solid Tumors. To explore the reasonable dosage of SHR-2017 Injection for Bone Metastases from Solid Tumors

Timeline

Start
2025-06-24
Primary completion
2025-12
Completion
2027-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Denosumab Monoclonal antibody
Subject SHR-2017 Unknown

Indications

No indication recorded.